

Listing of the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Canceled)

2. (Previously presented) A method of producing an agglomerated eukaryotic medium powder, said method comprising agglomerating a eukaryotic dry powder medium with a solvent, wherein the solvent comprises at least one lipid.

3 - 10. (Canceled)

11. (Previously presented) The method of claim 2, further comprising packaging said agglomerated powder.

12. (Previously presented) The method of claim 2, further comprising sterilizing said agglomerated powder.

13. (Previously presented) The method of claim 12, wherein said sterilization is performed after packaging said agglomerated powder.

14. (Previously presented) The method of claim 12, wherein said sterilization is accomplished by irradiation of said agglomerated powder with gamma rays until said agglomerated powder is rendered substantially sterile.

15-91. (Canceled)

92. (Currently amended) The method of claim 2, wherein when said agglomerated eukaryotic medium powder is reconstituted ~~upon reconstitution~~ with water, a the reconstituted eukaryotic medium is at a the desired pH for culturing a eukaryotic cell is produced.

93. (Currently amended) The method of claim 2, wherein said agglomerated eukaryotic medium powder comprises epidermal growth factor (EGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), insulin-like growth factor 1 (IGF-2) or nerve growth factor (NGF).

94-96. (Canceled)

97. (Previously presented) The method of claim 2, wherein the agglomerated eukaryotic medium powder is for culturing an animal cell.

98. (Previously presented) The method of claim 2, wherein the agglomerated eukaryotic medium powder is for culturing a mammalian cell.

99. (Previously presented) The method of claim 2, wherein the agglomerated eukaryotic medium powder is for culturing a human cell.

100. (Previously presented) The method of claim 2, wherein the agglomerated eukaryotic medium powder is for culturing a hybridoma cell.

101. (Previously presented) The method of claim 2, wherein the agglomerated eukaryotic medium powder is for culturing a cell selected from the group consisting of an insect cell, a nematode cell, a fungal cell, a plant cell and a yeast cell.

102. (Currently amended) The method of claim 2, wherein the agglomerated eukaryotic medium powder is for culturing a cell selected from the group consisting of an embryonic cell, a *Drosophila* cell, a *Spodoptera* cell, a *Trichoplusa* cell, a *C. elegans* cell, a Chinese hamster ovary (CHO) cell, a COS cell, a VERO cell, a baby hamster kidney (BHK) cell, an alveolar epithelial type 1 (AE-1) cell, a SP2/0 cell and a L5.1 cell.

103. (Previously presented) The method of claim 2, wherein the at least one lipid is a phospholipid.

104. (Previously presented) The method of claim 2, wherein the at least one lipid is a sphingolipid.

105. (Previously presented) The method of claim 2, wherein the at least one lipid is a fatty acid.

106. (Previously presented) The method of claim 2, wherein the at least one lipid is a cholesterol.

107. (Previously presented) The method of claim 2, comprising

- (a) placing the eukaryotic dry powder medium into a fluid bed apparatus;
- (b) introducing the solvent into the eukaryotic dry powder medium under conditions whereby the eukaryotic dry powder medium is moistened; and
- (c) drying the moistened eukaryotic dry powder medium, thereby producing an agglomerated eukaryotic medium powder.

108. (Previously presented) The method of claim 2, wherein the agglomerated eukaryotic medium powder exhibits reduced dusting and a larger particle size than does the eukaryotic dry powder medium.